soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm A emulation in Nature Medicine shows that treatment with and tirzepatide showed similar levels of benefit on in people at elevated cardiovascular risk with obesity and diabetes. Link NEJM Editorial Fellow Harleen Marwah,

Available at [Accessed on 29 April 2022] Arrythmia

This initial report lacked some information that will become available at the time of full study publication

However, the mechanism of action directly causes the most common side effects: gastrointestinal symptoms including oily stools, flatulence with discharge, faecal urgency, and increased bowel movements, particularly if patients consume high-fat meals

The dose may be adjusted up to a maximum of 3 mg per day, based on clinical response and tolerability (Table 1) [16,45]

Insulinomas are usually small in size, thereby complicating diagnosis using conventional imaging methods, such as CT, MRI, and EUS [1]